Skip to main content
$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
If you were already registered, log in here.

Short Interest

ASIC data, 6 Nov 2026

% Shorted

0.33% 0.01
vs 0.34% prior report

Most Shorted Rank

364th
of 717 shorted ASX stocks

Peak Short

8.10%
Aug 2023

Days to Cover

0.6
at 50d avg vol
Subject
IMU Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Imugene appoints experienced life sciences CFO Mike Tonroe

IMU Ann: IMU to Present New PD1-Vaxx Data at the WCLC 2022

IMU Ann: Appointment of Dr Sharon Yavrom as Clinical Scientist

IMU Ann: Investor Webinar - Final HER-Vaxx Overall Survival Results

IMU Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results

IMU Ann: Change of Director's Interest Notice - CW

IMU Ann: Change of Director's Interest Notice - LR

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD

IMU Ann: IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022

IMU Ann: IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT

IMU Ann: Letter to Shareholders

IMU Ann: IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL

IMU Ann: IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON

IMU Ann: Response to ASX Query

IMU Ann: Clarification Announcement

IMU Ann: Pause in Trading

IMU Ann: Termination of Supply Agreement

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

IMU Ann: Release of Securities from Escrow

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Dose Escalation in Phase 1 Clinical Trial of CHECKvacc

IMU Ann: Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia

IMU Ann: Investor webinar Imugene & Merck collaboration

IMU Ann: Imugene HER-Vaxx Clinical Trial Collaboration with Merck

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Half Yearly Report and Accounts

IMU Ann: Science Series CHECKvacc

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Change of Director's Interest Notice - JE

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Notice Under Section 708A

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: BPAY or EFT Process for IMUOC & IMUOD Option Holders

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Appointment of Dr Steven Cha as Chief Medical Officer

IMU Ann: Issue of Options under the Employee Share Option Plan

IMU Ann: Oncolytic Virotherapy CF33 Patent Granted in Japan

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: PD1-Vaxx Clinical Trial Supply Agreement with Roche

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS